Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Wilms tumor (nephroblastoma) miRNASeq

PROVIDER: PRJNA999470 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR25444600.fastq.gz	Fastqsanger.gz
	SRR25444601.fastq.gz	Fastqsanger.gz
	SRR25444602.fastq.gz	Fastqsanger.gz
	SRR25444603.fastq.gz	Fastqsanger.gz
	SRR25444604.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 72

Similar Datasets

Proteomic and phospho-proteomic raw data of Wilms tumor tissue and normal adjacent kidney tissue.

Project description:Proteomic and phospho-proteomic raw data of Wilms tumor tissue and normal adjacent kidney tissue from Wilms tumor patients.

| PXD063650 |

Circulating miRNA in serum of Wilms tumor patients

Project description:Abstract: Background: MiRNA signatures in human sera have been reported for various tumor diseases. Here we generated miRNA profiles analyzing 1205 mature miRNA transcripts of serum samples of Wilms tumor patients, taken prior and after chemotherapy according to SIOP protocol 2001. Using a feature subset selection filter approach we identified a minimal number of miRNAs with a maximum contribution for the classification between treated and untreated patients and between patients and controls. Results: Analyzing 1205 mature miRNAs, we separated controls and Wilms tumor patients prior chemotherapy with an accuracy of 0.81. We obtained a similar accuracy (0.82) for the separation between controls and sera of Wilms tumor patients after preoperative chemotherapy. We identified 23 miRNAs that were differentially expressed in both comparisons. Subset selection improved the overall classification accuracy between controls and Wilms tumor patients prior and after chemotherapy to 0.94 and 0.91, respectively. Subset selection also allowed separating between Wilms tumor patients prior and after chemotherapy with an accuracy of 0.98. Conclusion: Our analysis identified serum based miRNA signatures that allowed separating between controls, untreated Wilms tumor patients, and Wilms tumor patients after chemotherapy with high accuracy for each of these comparisons.

2014-12-31 | GSE48137 | GEO

miRNA profiles of Wilms tumor patients and controls

Project description:Blood-borne miRNA signatures have recently been reported for various tumor diseases. Here, we compared the miRNA signature in Wilms tumor patients prior to and after preoperative chemotherapy according to the SIOP protocol 2001. We did not find a significant difference between the miRNA signatures of both groups. However, both Wilms tumor patients prior to and after chemotherapy showed a miRNA signature different from that of healthy controls. The signature of Wilms tumor patients prior to chemotherapy showed an accuracy of 97.5% and of patients after chemotherapy an accuracy of 97.0%, each as compared to healthy controls. Our results provide evidence for a blood-borne Wilms tumor miRNA signature largely independent of four weeks preoperative chemotherapy treatment.

2013-07-22 | GSE38419 | GEO

DNA copy number variation from human Wilms' Tumor samples

Project description:Genome-wide DNA copy number was studied to determine whether the Wilms' tumor samples generally show normal copy number variation comparing to the colon tumor samples We used custom Nimblegen microarrays to determine the genome-wide DNA copy number in human Wilms' Tumor samples

2011-08-29 | GSE29374 | GEO

Proteasome inhibition sensitizes anaplastic Wilms tumor to actinomycin D

Project description:Wilms tumor is the most common kidney cancer in children, and anaplastic Wilms tumor is the most chemoresistant histological subtype. Here we explore how anaplastic Wilms tumor cells evade the common chemotherapeutic drug actinomycin D, which inhibits ribosomal biogenesis. We found that, when ribosomal capacity is limited by actinomycin D treatment, anaplastic Wilms tumor cells preferentially translate proteasome components and upregulate proteasome activity. Accordingly, increased proteasome levels are associated with anaplastic histology and with worse prognosis in Wilms tumor. Lastly, we show that the proteasome inhibitor bortezomib sensitizes cells to actinomycin D treatment both in vitro and in vivo.

2024-06-20 | GSE270330 | GEO

miRNA and Wilms' tumor

Project description:miRNA and Wilms' tumor

| PRJNA139175 | ENA

Transcriptomic Characterization of wilms tumor

Project description:Wilms tumor (WT) is the most common renal malignancy in children. So we aim to investigate the transcriptomic map of Wilms tumor.

2022-05-18 | GSE138869 | GEO

Bromodomain 4 inhibition leads to MYCN downregulation in Wilms’ tumor cells

Project description:We have undertaken a functional genomics approach to uncover novel therapeutic strategies efficacious for those patients with anaplastic Wilms’ tumor. Genomic analysis, in vitro chemical screens and microfluidic experiments demonstrate that MYCN over-expression in Wilms’ tumor can be modulated via BRD4 inhibition resulting in a reduction in Wilms’ tumor cell growth.

2020-08-12 | GSE156065 | GEO

DNA copy number variation from human Wilms' Tumor samples

2011-08-28 | E-GEOD-29374 | biostudies-arrayexpress

The transcriptomic data of the Wilms tumor cell line

Project description:We conducted RNA sequencing on Wilms tumor cells with or without EHMT2 knockdown to assess the impact of EHMT2 on gene expression in Wilms tumor.

2025-06-01 | GSE298590 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data